Biota revenues surge on rocketing Relenza sales
This article was originally published in Scrip
Executive Summary
A more than doubling in royalty income from global licensee GlaxoSmithKline for Relenza (zanamivir) helped boost Biota Holdings' revenues by 85% to A$83.3 million ($69.4 million) in the year to June 30th.